The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. (Q39135618)
Jump to navigation
Jump to search
scientific article published on 31 July 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. |
scientific article published on 31 July 2013 |
Statements
The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells (English)
Kathrin Zitzmann
Sandra Andersen
George Vlotides
Gerald Spöttl
Shengwen Zhang
Rakesh Datta
Burkhard Göke
Christoph J Auernhammer